Artificial intelligence (AI) could play an even greater role in clinical trials, as the technology appears underutilized in study conduct and the reporting of safety signals. The potential benefits of AI in clinical trials—faster timelines, lower burden on sites and patients and better data quality—are already well established. Regulatory credibility depends on genuine human cognitive engagement with AI outputs, not just a procedural sign-off.” Study conductAnd, under appropriate human oversight, AI can do more to make trials more efficient in Fakhouri’s view, with trial conduct being the obvious example. Third-party AIIncreasing use of AI in trials also means that software developers are playing a greater role in drug trials.